Immunological barriers of single‑species antigen design and the lethal blind spot of Filovirus variants The genus Orthoebolavirus comprises high‑risk pathogens that cause severe hemorrhagic fever and high case‑fatality rates in humans. Commercially available Ebola vaccines (e.g., Ervebo) target only the glycoprotein (GP) of Ebola virus (EBOV) as a monovalent antigen, inducing precise neutralizing antibodies. However, this monovalent approach fails when infection is caused by genetically distinct, highly lethal species such as Sudan virus (SUDV) or Bundibugyo virus (BDBV); humoral neutralization collapses completely, creating a critical technical bottleneck. Overcoming inter‑species structural heterogeneity to build a broad‑spectrum protective barrier has long been a blind spot in Filovirus governance.

GPs+NP multivalent mRNA‑LNP framework: dual activation of humoral and cellular immunity In May, a study published in the Proceedings of the National Academy of Sciences (PNAS) deployed a "multivalent" mRNA‑LNP platform that simultaneously encodes a panel of GP variants and the highly conserved nucleoprotein (NP). Using diversified guide RNA/mRNA computational designs, the platform expresses each species’ surface GP while packaging the minimally mutating internal NP within a single lipid nanoparticle (LNP) carrier. This synthetic‑biology optimization creates a hybrid immune engine that drives precise neutralizing antibody formation via GP (humoral immunity) and broad T‑cell activation via NP (cellular immunity) in parallel.

Non‑human primate (NHP) challenge demonstrates pan‑ebolavirus cross‑neutralizing titers and 100 % survival Pre‑clinical pharmacokinetic and pharmacodynamic studies in murine and NHP models showed that the [GPs+NP] multivalent vaccine induced robust, durable cross‑binding and neutralizing antibody titers against all Ebola, Sudan, and Bundibugyo virus species shortly after administration. Importantly, NP‑driven antigen‑specific CD8⁺ T‑cell responses constrained viral replication kinetics to baseline levels after intracellular entry. In lethal viral challenge experiments, the vaccinated cohort achieved perfect clinical scores and 100 % survival, confirming an uncompromised immunological shield.

Establishment of a plug‑and‑play vaccine standard and next‑generation IND guidance The structural immunology and nucleic‑acid delivery dataset generated by this work is poised to disrupt global biotech R&D and LNP pipeline businesses. By resetting vaccine development from single‑antigen updates to a modular architecture that integrates surface‑variable antigens with conserved internal antigens, the platform creates a new standard for Disease X preparedness. The derived neutralization‑weight matrix for each multivalent antigen combination will serve as a computational re‑programming reference for rapid mRNA sequence redesign against emerging Ebola variants, enabling real‑time screening engines. This asset will become a core reference for calculating throughput thresholds in multinational regulatory pathways and dramatically shortening accelerated approval timelines for high‑risk viral therapeutics.